Baxendale P M, Jacobs H S, James V H
Clin Endocrinol (Oxf). 1983 May;18(5):447-57. doi: 10.1111/j.1365-2265.1983.tb02874.x.
Sensitive radioimmunoassays (RIA) have been developed to measure salivary and plasma androstenedione and dihydrotestosterone levels in normal women, women with polycystic ovaries (PCO) and idiopathic hirsutism, and patients on antiandrogen therapy. There was a highly significant correlation (r = 0.92, P less than 0.001) between the concentration of androstenedione in saliva and the unbound concentration in plasma. The unbound plasma androstenedione was measured in the dialysate by RIA and ranged from 6.0-10.4% of the total concentration. Salivary and plasma androstenedione levels in patients with PCO (185 +/- 72 pg/ml (n = 11) and 3262 +/- 814 pg/ml (n = 12) respectively) and in those with hirsutism (151 +/- 110 pg/ml (n = 25) and 2177 +/- 1096 pg/ml (n = 25) were significantly higher than levels in normal women (78 +/- 30 pg/ml (n = 18) and 787 +/- 355 pg/ml (n = 18). A good correlation (r = 0.82, P less than 0.001) was also found between salivary and unbound plasma dihydrotestosterone concentrations. Salivary and plasma dihydrotestosterone levels in patients with PCO (8.2 +/- 3.3 pg/ml (n = 9) and 167 +/- 45 pg/ml (n = 11) respectively and hirsutism (6.0 +/- 2.1 pg/ml (n = 14) and 176 +/- 69 pg/ml (n = 17) were significantly higher than levels in normal women (4.5 +/- 1.3 pg/ml (n = 17) and 90 +/- 44 pg/ml (n = 16), although there was a large overlap between groups. A similar decrease was observed in salivary and plasma androstenedione levels after treatment with cyproterone acetate (CA) and ethinyl oestradiol (EE) for 3 months. Plasma dihydrotestosterone levels remained elevated in 47% of treated women whereas only 21% of cases had raised salivary dihydrotestosterone levels. It is concluded that, as with testosterone salivary androstenedione and dihydrotestosterone measurements give a good reflection of their biologically active levels in normal, hyperandrogenic and CA + EE treated women.
已开发出灵敏的放射免疫分析法（RIA）来测量正常女性、多囊卵巢（PCO）女性、特发性多毛症女性以及接受抗雄激素治疗患者的唾液、血浆中雄烯二酮和双氢睾酮水平。唾液中雄烯二酮浓度与血浆中游离浓度之间存在高度显著相关性（r = 0.92，P < 0.001）。通过RIA测量透析液中游离血浆雄烯二酮，其占总浓度的6.0 - 10.4%。PCO患者（分别为185 ± 72 pg/ml（n = 11）和3262 ± 814 pg/ml（n = 12））以及多毛症患者（分别为151 ± 110 pg/ml（n = 25）和2177 ± 1096 pg/ml（n = 25））的唾液和血浆雄烯二酮水平显著高于正常女性（分别为78 ± 30 pg/ml（n = 18）和787 ± 355 pg/ml（n = 18））。唾液和游离血浆双氢睾酮浓度之间也发现有良好相关性（r = 0.82，P < 0.001）。PCO患者（分别为8.2 ± 3.3 pg/ml（n = 9）和167 ± 45 pg/ml（n = 11））以及多毛症患者（分别为6.0 ± 2.1 pg/ml（n = 14）和176 ± 69 pg/ml（n = 17））的唾液和血浆双氢睾酮水平显著高于正常女性（分别为4.5 ± 1.3 pg/ml（n = 17）和90 ± 44 pg/ml（n = 16）），尽管各组之间存在较大重叠。用醋酸环丙孕酮（CA）和炔雌醇（EE）治疗3个月后，唾液和血浆雄烯二酮水平出现类似下降。47%接受治疗的女性血浆双氢睾酮水平仍升高，而仅有21%的病例唾液双氢睾酮水平升高。结论是，与睾酮一样，唾液中雄烯二酮和双氢睾酮的测量能很好地反映正常、高雄激素血症以及CA + EE治疗女性中它们的生物活性水平。
